LivaNova公共 LIVN 深 沪
等待开盘 08-07 09:30:00 美东时间
47.36
+4.750
+11.15%
华盛通- 最 高48.50
- 今 开46.10
- 成交量 141.59万股
- 最 低 45.64
- 昨 收 42.61
- 总市值 25.82亿
- 52周最高 57.3498
- 市盈率 静 40.87
- 换手率 2.60%
- 52周最低 32.48
- 委 比 -16.29%
- 总股本 5452.57万
- 历史最高 131.54
- 量 比 1.43
- 振 幅 6.71%
- 历史最低 23.58
- 每 手 1
- 风险率 5.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LivaNova shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.
LivaNova shares are trading higher after the company reported better-than-expec...
08-06 23:31
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 0.1% on...
08-06 22:42
LivaNova Raises FY2025 Adj EPS Guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 Est; Raises FY2025 Sales Guidance from $1.316B-$1.341B to $1.353B-$1.366B vs $1.328B Est
LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 analyst estimate. Raises FY2025 sales outlook from $1.316 billion-$1.341 billion to $1.353 billion-$1.366 billion vs $1.328
08-06 18:02
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
LivaNova Shareholders Approve Key Incentive Plans at AGM
LivaNova ( ($LIVN) ) has issued an announcement. On June 11, 2025, LivaNova PLC...
06-12 05:17
LivaNova Initiates Process With U.S. CMS To Seek Reconsideration Of National Medicare Coverage For VNS Therapy In Unipolar Patients With Treatment-Resistant Depression
Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results
06-04 20:12
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
Wolfe Research Upgrades LivaNova to Outperform, Announces $60 Price Target
Wolfe Research analyst Mike Polark upgrades LivaNova (NASDAQ:LIVN) from Peer Perform to Outperform and announces $60 price target.
05-21 00:15
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
